Drugs / 68Ga-FAPI-RGD
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06638034 | May 2024 → Jan 2025 overdue | — | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05543954 | Sep 2022 → Dec 2025 overdue | lung neoplasm | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-FAPI-RGD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05543954 ↗ |
| Modality | Diagnostic / imaging agent | “a novel dual-target imaging agent 68Ga-FAPI-RGD was used for PET/CT imaging of lung cancer” NCT05543954 ↗ |
| Route | Intravenous | “Intravenous injection of 68Ga-FAPI-RGD” NCT05543954 ↗ |